Demonstrations at Columbia University, are a symptom of a culture that is focused more on destruction than on creation and innovation
Article Archive
Collection of published news articles written by Dr Shendelman
Shoshana Shendelman is an entrepreneur and scientist. Shoshana is the founder and leader of multiple biotech companies, pioneering drug development for rare and underserved diseases, with a strong academic background in neurobiology and molecular mechanisms of neurodegenerative diseases.
- Universities stand at a crossroads, facing a choice between fostering open dialogue and innovation or allowing a culture of chaos and intimidation to take hold.
- Our understanding of diseases and technologies has advanced substantially over the past decade, but FDA regulations haven’t changed much. It’s imperative that our regulatory policies align with our scientific potential.
- Biotech advancements often face delays due to bureaucracy, hindering the development of necessary therapies. Now is the time for us to overhaul the archaic procedural measures.
Permit Bureaucracy Means People Die Waiting for Therapeutic Advances
Published on: Real Clear MarketsWith over 30 million Americans suffering from rare diseases, 95% of whom lack approved treatments, time is of the essence. FDA approvals typically take a decade and require extensive funding, plagued by linear reviews and outdated standards. These patients have no options.- Our understanding of diseases and technologies has advanced substantially over the past decade, but FDA regulations haven’t changed much. It’s imperative that our regulatory policies align with our scientific potential.
